Stock Update: Merck & Co Inc (NYSE:MRK) – Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant …

[at noodls] – WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.–(BUSINESS WIRE)– Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) … Read more on this. . . . → Read More: Stock Update: Merck & Co Inc (NYSE:MRK) – Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant … Similar Articles: Company Update (NYSE:MRK): Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29 Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14 Company Update: Merck & Co. Inc. (NYSE:MRK) – Novartis Veterinary Unit Said to Draw Interest From Merck, Lilly